Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1051 studies found for:    EGF
Show Display Options
Rank Status Study
1 Recruiting Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer
Condition: Non Small Cell Lung Cancer
Interventions: Drug: EGF816;   Drug: INC280;   Drug: Nivolumab
2 Recruiting Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Biological: EGF Vaccine
3 Recruiting Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects
Conditions: Non-small Cell Lung Cancer;   Pancreatic Cancer;   Colorectal Cancer
Interventions: Drug: Arm 1;   Drug: Arm 2
4 Recruiting Study of Safety and Efficacy of EGF816 in Combination With INC280 in Non-small Cell Lung Cancer Patients With EGFR Mutation.
Condition: Non Small Cell Lung Cancer
Interventions: Drug: INC280;   Drug: EGF816
5 Completed EGF Ointment for Erlotinib Skin Lesion
Conditions: Non-small Cell Lung Cancer;   Pancreatic Cancer
Intervention: Drug: Epidermal growth factor (EGF) ointment
6 Completed Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma
Conditions: Colorectal Cancer;   Carcinoma
Intervention: Drug: ABX-EGF
7 Completed
Has Results
ABX-EGF (Panitumumab) Monotherapy in Subjects With Metastatic Colorectal Cancer
Conditions: Colorectal Cancer;   Metastases
Intervention: Drug: ABX-EGF (panitumumab)
8 Recruiting A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies
Condition: Advanced Non-small Cell Lung Cancer (NSCLC)
Intervention: Drug: EGF816
9 Terminated A Randomized Trial to Study the Safety and Efficacy of EGF Cancer Vaccination in Late-stage (IIIB/IV) Non-small Cell Lung Cancer Patients
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Biological: Therapeutic EGF Vaccine (Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine)
10 Recruiting A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
Conditions: Colorectal Cancer;   Triple Negative Breast Cancer;   Non-small Cell Lung Cancer (Adenocarcinoma)
Interventions: Biological: PDR001;   Biological: ACZ885;   Biological: CJM112;   Drug: TMT212;   Drug: EGF816
11 Completed ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Conditions: Non-small Cell Lung Cancer;   Neoplasm Metastasis;   Lung Cancer
Intervention: Drug: ABX-EGF
12 Completed Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal Cancer
Condition: Colorectal Cancer
Intervention: Drug: ABX-EGF
13 Completed Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer
Condition: Metastatic Colorectal Cancer
Intervention: Drug: ABX-EGF (panitumumab)
14 Completed ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body
Condition: Prostate Cancer
Intervention: Drug: ABX-EGF
15 Unknown  A Physiological Study on Downregulation of EGF-receptors in the Skin by Topical Exposition With EGF
Condition: Plaque Psoriasis
Interventions: Drug: Human recombinant epidermal growth factor;   Other: Placebo cream
16 Completed
Has Results
Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer
Conditions: Colorectal Cancer;   Metastases
Interventions: Other: Best supportive care;   Drug: Panitumumab
17 Completed
Has Results
Effect of EGF With Silver Sulfadiazine Cream Compared With Silver Zinc Sulfadiazine Cream for Treatment of Burn Wound
Condition: Deep Partial Thickness Burn
Interventions: Drug: Epidermal growth factor with silver sulfadiazine cream;   Drug: Silver zinc sulfadiazine cream
18 Completed
Has Results
Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Drug: Irinotecan;   Biological: Panitumumab;   Drug: 5-Fluorouracil;   Drug: Leucovorin
19 Completed ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Conditions: Non-Small Cell Lung Cancer;   Neoplasm Metastasis;   Lung Cancer
Interventions: Drug: ABX-EGF;   Drug: paclitaxel;   Drug: carboplatin
20 Completed
Has Results
Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy
Conditions: Colorectal Cancer;   Metastatic Cancer
Intervention: Biological: Panitumumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years